Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage high-risk extranodal NK/T cell lymphoma, nasal type
Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type|Early-stage|High-Risk Cancer
DRUG: Anti-PD-1 monoclonal antibody|DRUG: Pegaspargase|DRUG: Gemcitabine|DRUG: Oxaliplatin|RADIATION: Involved site radiotherapy
Complete Response rate after 3 cycles of Anti-PD-1 antibody and P-GEMOX therapy, To evaluate the complete response (CR) rate after 3 cycles of Anti-PD-1 antibody and P-GEMOX therapy according to Lyric 2016 criteria, At the end of Cycle 3 (each cycle is 14 days)
Progression-free survival rate at year 2 after enrollment, 2y-PFS, From enrollment to disease progression or any death, 2 year|Overall Survival rate at year 2/5 after enrollment，2y-/5y-OS, From enrollment to death, 2-year, 5-year|acute toxicity, evaluated according to the CTCAE criteria, From enrollment to 3 months after treatment|Quality of Life，QoL, evaluated according to EORTC-QLQ-HN35, baseline, 1/3/6/12/24 months after treatment|Quality of Life，QoL, evaluated according to EORTC-QLQ-C30, baseline, 1/3/6/12/24 months after treatment
biomarkers (single cell transcriptomics), baseline, 2 years
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage high-risk extranodal NK/T cell lymphoma, nasal type